On 4 May 2026, the European Commission published MDCG 2026-3, a new supplementary guidance under Regulation (EU) 2017/745 (MDR), mandating biocompatibility revalidation for all medical ultrasound probes — including portable, linear, and phased-array types — effective from August 2026. This development directly affects manufacturers exporting to the EU, especially those based in China, and signals heightened regulatory scrutiny on material-level conformity for reusable and single-use contact devices.

Event Overview

The European Commission issued MDCG 2026-3 on 4 May 2026. The guidance requires that, starting in August 2026, all medical ultrasound probes placed on the EU market must be accompanied by a standalone biocompatibility revalidation report per ISO 10993-1:2023. This report must specifically cover newly introduced encapsulation materials and coating processes used in subsequent production batches. Chinese probe manufacturers are explicitly required to complete supplementary biocompatibility testing prior to export clearance.

Industries Affected

Ultrasound Probe Manufacturers (OEMs & Contract Manufacturers)

Manufacturers are directly responsible for compliance. Any change in encapsulation resin, acoustic lens coating, or surface treatment across production batches now triggers a full ISO 10993-1:2023 revalidation — not just a gap assessment or risk-based justification. Impact includes extended time-to-market, increased testing costs, and potential delays in CE marking renewal or new submissions.

Material Suppliers (Encapsulants, Coating Formulations)

Suppliers of polymeric encapsulants, hydrogel coatings, or acoustic matching layers face stricter traceability and documentation demands. Downstream customers will require updated material specifications, lot-specific toxicological profiles, and evidence of process stability — particularly where proprietary formulations or minor process adjustments occur between batches.

Testing Laboratories & Notified Bodies

Laboratories accredited for ISO 10993 testing will see increased demand for full-series biocompatibility evaluations (cytotoxicity, sensitization, irritation, genotoxicity) rather than targeted tests. Notified Bodies must verify that revalidation reports align with actual production records and reflect changes beyond nominal revisions — such as supplier switches or curing parameter deviations.

Export Compliance & Regulatory Affairs Service Providers

Firms supporting Chinese and other non-EU manufacturers face higher workload complexity. Supporting documentation must now include explicit mapping between batch-level manufacturing records and corresponding biocompatibility test reports — requiring tighter integration between quality management systems (QMS) and regulatory dossiers.

Key Considerations and Recommended Actions

Monitor official updates on MDCG 2026-3 implementation timelines

MDCG documents are guidance, not law; however, Notified Bodies routinely enforce them as de facto requirements. Stakeholders should track whether the European Commission issues further clarifications on what constitutes a ‘material change’ or whether transitional arrangements apply for legacy designs already certified under MDR.

Identify and document all encapsulation and coating process variables subject to revalidation

Manufacturers should audit current production records to identify which parameters — e.g., resin vendor, catalyst ratio, UV-curing dose, plasma treatment duration — may trigger revalidation under the new guidance. Maintaining a controlled change log is essential for demonstrating proactive compliance.

Engage accredited labs early for ISO 10993-1:2023 testing capacity planning

Full biocompatibility revalidation typically requires 8–12 weeks. Given anticipated demand spikes ahead of the August 2026 deadline, manufacturers should initiate lab engagement now — particularly for cytotoxicity and sensitization assays, which have longer lead times due to animal-derived reagents or specialized cell lines.

Review technical documentation against MDCG 2026-3’s scope definition

The guidance applies to *all* ultrasound probes intended for direct patient contact, regardless of intended use (diagnostic, therapeutic, or intraoperative). Firms must confirm whether their product classification falls within the scope — especially for hybrid devices (e.g., probe-integrated ablation systems) where biocompatibility evaluation may have previously been scoped to only the transducer housing.

Editorial Perspective / Industry Observation

Observably, MDCG 2026-3 reflects a tightening of MDR’s post-market surveillance logic: it shifts focus from device-level conformity to batch-level material consistency. Analysis shows this is less a sudden policy reversal and more an operational clarification — reinforcing existing MDR Annex I requirements (General Safety and Performance Requirements, GSPRs) regarding chemical safety and biological risk. From an industry perspective, this guidance functions primarily as a signal: it indicates that Notified Bodies are increasingly scrutinizing how manufacturers control and justify material-related changes over time. It is not yet a finalized legal obligation, but its enforcement is highly probable given alignment with established harmonized standards and recent MDCG precedent.

Consequently, industry stakeholders should treat MDCG 2026-3 not as an isolated update, but as part of a broader trend toward granular, process-linked biocompatibility assurance — one that prioritizes empirical validation over theoretical risk mitigation.

Conclusion

This guidance underscores that regulatory compliance for ultrasound probes in the EU is evolving from a static certification exercise into an ongoing, process-integrated verification requirement. For manufacturers, suppliers, and service providers alike, the priority is no longer just achieving CE marking — it is sustaining demonstrable control over material and process variables across the entire product lifecycle. Currently, this development is best understood as a procedural escalation grounded in existing MDR principles, not a fundamental shift in regulatory philosophy.

Information Sources

Main source: European Commission, MDCG 2026-3 Guidance Document on Biocompatibility Revalidation for Medical Ultrasound Probes (published 4 May 2026). Note: Implementation details, including Notified Body interpretation and acceptance criteria for revalidation reports, remain subject to ongoing observation and may evolve through Q&A publications or national competent authority statements.